Skip to main content
. 2021 Jul 13;12(7):698. doi: 10.1038/s41419-021-03998-w

Fig. 2. Sorafenib does not induce ferroptosis in HT1080 cells.

Fig. 2

a Immunoblots of xCT in wild-type (WT), SLC7A11 knockout (SLC7A11KO), and SLC7A11 overexpressing (SLC7A11OE) HT1080 cells. Valosin-containing protein (VCP) was used as a loading control. b Cystine uptake activity of WT and SLC7A11OE HT1080 cells in the presence of either 10 µM erastin or sorafenib. Data are presented as mean ± s.d. (n = 4). c Cell viability of WT, SLC7A11KO, and SLC7A11OE HT1080 cells treated with indicated concentrations of sorafenib, sulfasalazine, or erastin, in the absence or presence of 50 μM β-mercaptoethanol (β-ME), 1 μM Lip-1, or 100 μM DFP for 24 h. Data are presented as mean ± s.d. of n = 3 wells of a 96-well plate from one representative of three independent experiments.